NetworkNewsBreaks – Odyssey Health Inc. (ODYY) F
Post# of 85
Odyssey Health (OTC: ODYY) has filed for United States and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device (“Nasal Device”). As previously announced, Odyssey’s recently completed phase I study to treat concussion successfully used Odyssey’s Nasal Device and drug combination. “We were very pleased with the functionality and performance of the Nasal Device during the phase I study and its administration of Odyssey’s PRV-002 concussion drug,” said Michael Redmond, CEO of Odyssey. “The ability to get drugs for neurological conditions delivered directly into the brain rapidly at effective levels while simultaneously having less concern for side effects is a huge advantage in the development of safe and efficacious treatments. Odyssey’s novel Nasal Device provides that opportunity and advantage.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer